Aclaris Therapeutics, Inc. (NasdaqGS:ACRS) announced that it is conducting a strategic review of its business to determine how to optimally deploy its capital to maximize shareholder return. On a preliminary unaudited basis, as of December 31, 2023, Aclaris? aggregate cash, cash equivalents and marketable securities was approximately $182 million.